On the afternoon of August 18, Enhua Pharmaceutical announced that the company recently received the “Drug Clinical Trial Approval Notice” for the Class 1 innovative drug NH130 citrate tablets and agreed to conduct clinical trials. Application indications: Intended to treat schizophrenia; intended to treat Alzheimer's psychotic disorder. In addition, the company recently received the “Drug Clinical Trial Approval Notice” for the Class 1 innovative drug NH302 injection and agreed to conduct clinical trials for acute pain.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.